---
layout: default
title: Dimethicone
parent: 僅模型預測 (L5)
nav_order: 118
evidence_level: L5
indication_count: 0
---

# Dimethicone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# DIMETHICONE: Repurposing Evaluation — Insufficient Data for Assessment

## One-Sentence Summary

DIMETHICONE (DB11074) is a silicone-based polymer widely used as a topical skin protectant and pharmaceutical excipient.
However, **no TxGNN repurposing predictions were generated** for this compound,
and **no approved indications are registered in Taiwan**, making a standard repurposing evaluation impossible at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no registered indications found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — no predictions generated) |
| Taiwan Market Status | 未上市 (Not marketed in Taiwan) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated?

DIMETHICONE is classified primarily as an **inactive ingredient / excipient** rather than a pharmacologically active compound with a defined disease-modifying mechanism of action. TxGNN's knowledge graph is built on drug–disease relationships mediated by biological targets (proteins, pathways, genes); compounds that act as physical barriers, lubricants, or formulation aids — rather than binding to specific molecular targets — are typically absent from or sparsely represented in the underlying graph.

Three structural issues limit TxGNN's ability to generate meaningful predictions for DIMETHICONE:

1. **No known molecular target**: Dimethicone functions mechanically (surface coating, anti-foam, moisture barrier) rather than through receptor binding or enzyme inhibition. Without a target node in the knowledge graph, no disease edges can be traversed.
2. **No registered disease indication**: The Evidence Pack contains an empty `original_indications` array, meaning there is no seed indication to anchor a repurposing trajectory.
3. **Taiwan regulatory absence**: With zero licenses in Taiwan, there is no local pharmacovigilance or post-marketing data to supplement model predictions.

---

## Taiwan Market Information

No authorizations found. DIMETHICONE has not been registered as a standalone active pharmaceutical ingredient in Taiwan.

---

## Safety Considerations

No drug interaction data was identified. Please refer to the relevant package insert or excipient safety data sheet (SDS) for handling and formulation-specific safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN generated zero repurposing predictions for DIMETHICONE, and the compound lacks the pharmacological target profile required for disease-indication matching. Without a mechanism of action and without a seed indication, there is no scientifically defensible basis to proceed with a repurposing dossier.

**To proceed, the following is needed:**

- **Clarify intended use context**: Confirm whether DIMETHICONE is being evaluated as an *active ingredient* (e.g., wound healing, seborrheic dermatitis) or as an *excipient* in a formulation containing a separate active drug. If the latter, the active ingredient should be the subject of this report.
- **MOA data**: Retrieve detailed pharmacological classification from DrugBank API (DG002 remediation); if no biological target exists, the compound should be flagged as non-actionable for TxGNN.
- **TFDA/package insert data**: Parse the TFDA package insert PDF identified in query log (query ID 4, status: success) to extract any approved indication text, warnings, and contraindications (DG001 remediation).
- **Alternative evidence sources**: If a topical/dermatological indication is the goal, conduct a manual literature search (PubMed, Cochrane) for clinical studies of dimethicone in skin conditions, head lice (Hedrin®), or gastrointestinal gas — areas where clinical evidence does exist outside the TxGNN framework.
- **Re-run TxGNN**: After resolving data gaps and confirming the indication context, re-submit with a populated `original_indications` field to enable prediction traversal.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

